Prognostic Value of Inflammatory Markers in Patients with Advanced Triple Negative Breast Cancer
Overview
This study investigates the prognostic significance of inflammatory markers in patients with metastatic triple-negative breast cancer (TNBC).
Background
Triple-negative breast cancer (TNBC) is a subtype of breast cancer known for its aggressive behavior and poor prognosis, accounting for approximately 15% of all breast cancer cases.
Data Highlights
Inflammatory Index
Cut-off Value
PFS Association (p-value)
OS Association (p-value)
NLR
≥3
<0.0001
<0.0001
MLR
≥0.34
<0.0001
0.0006
PLR
≥210
0.0002
0.002
SII
≥836
<0.0001
0.001
Key Findings
Median progression-free survival (PFS) was 8.6 months in the study population.
Median overall survival (OS) was 17.7 months.
High NLR (≥3) was significantly associated with lower PFS and OS.
High MLR (≥0.34) and PLR (≥210) also correlated with poorer survival outcomes.
SII (≥836) was another significant marker for reduced PFS and OS.
In multivariable analysis, NLR, SII, and MLR remained significant predictors of OS.
Clinical Implications
Inflammatory markers such as NLR, PLR, MLR, and SII may serve as prognostic biomarkers in patients with metastatic TNBC.
Conclusion
The study highlights the potential of inflammatory ratios as prognostic indicators in metastatic TNBC.
by Caterina Gianni, Emanuela Scarpi, Eva Blondeaux, Michela Palleschi, Filippo Merloni, Lorenzo Gasperoni, Fabio Puglisi, Elena Collovà, Palma Pugliese, Francesco Cognetti, Irene Giannubilo, Tommaso Ruelle, Lucia Del Mastro, Claudia Bighin, Antonino Musolino, Ugo De Giorgi
In the first installment of a new series on the investment environment in cell and gene therapy, Circio CEO Erik Wiklund explains how he had to get creative to raise funds in a difficult biotech market
